What is Ocean Biomedical Inc.'s earnings per share (EPS)?

Ocean Biomedical Inc. (OCEA) reported diluted earnings per share of $-0.34 for fiscal year 2024. This represents a 92.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ocean Biomedical Inc. Financials

OCEA

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2025 Currency USD FYE December

This page shows Ocean Biomedical Inc. (OCEA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 0/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Ocean Biomedical Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

Ocean Biomedical Inc.'s current ratio of 0.02 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Interest Coverage At Risk

-1.9x

Ocean Biomedical Inc. earns $-1.9 in operating income for every $1 of interest expense (-$3.8M vs $2.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.34

YoY+92.2%

Ocean Biomedical Inc. earned $-0.34 per diluted share (EPS) in fiscal year 2024. This represents an increase of 92.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$200K

YoY-80.0%

Ocean Biomedical Inc. held $200K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

35M

YoY+0.6%

Ocean Biomedical Inc. had 35M shares outstanding in fiscal year 2024. This represents an increase of 0.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$26K

YoY-96.3%

Ocean Biomedical Inc. invested $26K in research and development in fiscal year 2024. This represents a decrease of 96.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

OCEA Income Statement

Metric	FY24	FY23	FY22
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$26K-96.3%	$709K-91.6%	$8.4M
SG&A Expenses	$3.8M-60.3%	$9.5M+23.2%	$7.7M
Operating Income	-$3.8M+62.8%	-$10.2M	N/A
Interest Expense	-$2.0M-4192.0%	$50K+7135.9%	$691
Income Tax	N/A	N/A	N/A
Net Income	N/A	N/A	N/A
EPS (Diluted)	$-0.34+92.2%	$-4.35-487.8%	$-0.74

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$18K	N/A	N/A	N/A	$26K	N/A	$305K+989.3%	$28K
SG&A Expenses	$940K	N/A	$768K+12.6%	$682K+19.9%	$569K	N/A	$2.4M-16.2%	$2.8M
Operating Income	-$958K	N/A	-$768K-12.6%	-$682K-14.6%	-$595K	N/A	-$2.7M+6.3%	-$2.8M
Interest Expense	$343K	N/A	-$461K+10.5%	-$515K-180.8%	$637K	N/A	$0-100.0%	$24K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	-$3.7M	N/A	$13.0M	N/A	N/A	N/A
EPS (Diluted)	$-0.09	N/A	$-0.13+79.4%	$-0.63-231.3%	$0.48	N/A	$-0.53-23.3%	$-0.43

OCEA Balance Sheet

Metric	FY24	FY23	FY22
Total Assets	$902K-83.6%	$5.5M+198.6%	$1.8M
Current Assets	$812K-61.5%	$2.1M+14.5%	$1.8M
Cash & Equivalents	$200K-80.0%	$1.0M+2841.2%	$34K
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$98.5M+2.3%	$96.3M+660.3%	$12.7M
Current Liabilities	$33.9M+12.9%	$30.0M+137.0%	$12.7M
Long-Term Debt	N/A	N/A	N/A
Total Equity	-$97.6M-7.6%	-$90.8M-738.9%	-$10.8M
Retained Earnings	-$205.5M-4.8%	-$196.1M-140.3%	-$81.6M

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Total Assets	$1.6M+75.4%	$902K-20.3%	$1.1M-38.8%	$1.9M-37.2%	$2.9M-46.4%	$5.5M+433.6%	$1.0M-52.3%	$2.2M
Current Assets	$1.5M+83.7%	$812K-22.1%	$1.0M-18.4%	$1.3M-29.0%	$1.8M-14.7%	$2.1M+104.6%	$1.0M-52.3%	$2.2M
Cash & Equivalents	$800K+300.0%	$200K0.0%	$200K0.0%	$200K+952.6%	$19K-98.1%	$1.0M0.0%	$1.0M-9.1%	$1.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$94.0M-4.6%	$98.5M+1.2%	$97.4M+3.0%	$94.6M+20.2%	$78.7M-18.2%	$96.3M+26.2%	$76.3M+19.5%	$63.8M
Current Liabilities	$26.6M-21.6%	$33.9M+6.5%	$31.8M+3.5%	$30.7M+2.1%	$30.1M+0.3%	$30.0M-2.7%	$30.9M+3.6%	$29.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$92.4M+5.3%	-$97.6M-1.4%	-$96.3M-3.8%	-$92.7M-22.4%	-$75.8M+16.5%	-$90.8M-20.7%	-$75.2M-22.0%	-$61.7M
Retained Earnings	-$213.8M-4.0%	-$205.5M-0.8%	-$204.0M-1.8%	-$200.3M-9.4%	-$183.1M+6.6%	-$196.1M-9.4%	-$179.2M-8.5%	-$165.1M

OCEA Cash Flow Statement

Metric	FY24	FY23	FY22
Operating Cash Flow	-$4.2M+55.7%	-$9.4M-849.5%	-$993K
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	-$2.1M
Financing Cash Flow	$3.4M-67.3%	$10.4M+975.4%	$967K
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Operating Cash Flow	-$356K+85.5%	-$2.4M-155.8%	-$957K-230.0%	-$290K+40.2%	-$485K+44.0%	-$866K+23.4%	-$1.1M+76.4%	-$4.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$909K-62.6%	$2.4M	N/A	N/A	N/A	$839K	$0-100.0%	$6.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OCEA Financial Ratios

Metric	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A
Current Ratio	0.02-0.0	0.07-0.1	0.15
Debt-to-Equity	-1.01+0.1	-1.06+0.1	-1.17
FCF Margin	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	-327.2%	N/A	441.2%	N/A	N/A	N/A
Current Ratio	0.06+0.0	0.020.0	0.030.0	0.04-0.0	0.06-0.0	0.07+0.0	0.03-0.0	0.07
Debt-to-Equity	-1.020.0	-1.010.0	-1.010.0	-1.02+0.0	-1.04+0.0	-1.06-0.0	-1.01+0.0	-1.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$97.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Regen Biopharma RGBPP

Galera Therapeutics, Inc. GRTX

$6.5M

Ayala Pharm ADXS

$25.7M

Appili Ther APLIF

$2.1M

Vaccinex Inc VCNX

$2.8M

Frequently Asked Questions

What is Ocean Biomedical Inc.'s operating cash flow?

Ocean Biomedical Inc. (OCEA) generated -$4.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Ocean Biomedical Inc.'s total assets?

Ocean Biomedical Inc. (OCEA) had $902K in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Ocean Biomedical Inc. spend on research and development?

Ocean Biomedical Inc. (OCEA) invested $26K in research and development during fiscal year 2024.

How many shares does Ocean Biomedical Inc. have outstanding?

Ocean Biomedical Inc. (OCEA) had 35M shares outstanding as of fiscal year 2024.

What is Ocean Biomedical Inc.'s current ratio?

Ocean Biomedical Inc. (OCEA) had a current ratio of 0.02 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Ocean Biomedical Inc.'s debt-to-equity ratio?

Ocean Biomedical Inc. (OCEA) had a debt-to-equity ratio of -1.01 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ocean Biomedical Inc.'s cash runway?

Based on fiscal year 2024 data, Ocean Biomedical Inc. (OCEA) had $200K in cash against an annual operating cash burn of $4.2M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Ocean Biomedical Inc.'s debt-to-equity ratio negative or unusual?

Ocean Biomedical Inc. (OCEA) has negative shareholder equity of -$97.6M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Can Ocean Biomedical Inc. cover its interest payments?

Ocean Biomedical Inc. (OCEA) has an interest coverage ratio of -1.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Ocean Biomedical Inc.?

Ocean Biomedical Inc. (OCEA) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.